Stanford Medicine Outpatient Center
Stanford Medicine Outpatient Center
Redwood City, California, United States4 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (Also Known as RO7790121) in Participants With Moderately to Severely Active Ulcerative Colitis | Moderately to Severely Active Ulcerative Colitis | Active, not recruiting | Phase 3 | 2026-10-02 | NCT06588855 | |
| A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease | Moderately to Severely Active Crohns Disease | Recruiting | Phase 3 | 2026-09-28 | NCT06819891 | |
| Extended Emergence Strategy on Post-Anesthesia Care Unit Events After Outpatient Orthopedic Surgery | Confusion, Emergence Delirium, Neurobehavioral Manifestations, Neurologic Manifestations, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Postoperative Complications, Signs and Symptoms, cognitive disorder, delirium, nervous system disorder, psychiatric disorder | Not yet recruiting | Not applicable | 2026-05-22 | NCT07533370 | |
| An Extension Study to Learn About the Long-Term Safety of Fazirsiran and if Fazirsiran Can Help People With Alpha-1 Antitrypsin Liver Disease | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Digestive System Diseases, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Subcutaneous Emphysema, alpha 1-antitrypsin deficiency, hereditary disease, liver disorder, lung disorder, pulmonary emphysema, respiratory system disorder | Active, not recruiting | Phase 3 | 2025-10-14 | NCT05899673 |